A phase II study of irinotecan-cisplatin plus durvalumab for untreated extensive-stage small cell lung cancer (WJOG13520L, REBORN trial)

被引：0

作者：

Tachihara, M. ^{[1
]}

Shoda, H. ^{[2
]}

Akazawa, Y. ^{[3
]}

Ota, T. ^{[4
]}

Oki, M. ^{[5
]}

Sato, Y. ^{[6
]}

Sugawara, S. ^{[7
]}

Ikeda, S. ^{[8
]}

Yokoyama, T. ^{[9
]}

Kaneda, H. ^{[10
]}

Itoh, S. ^{[11
]}

Bessho, A. ^{[12
]}

Katakami, N. ^{[13
]}

Morita, S. ^{[14
,15
]}

Nakagawa, K. ^{[16
]}

Okamoto, I. ^{[17
]}

Yamamoto, N. ^{[18
]}

机构：

[1] Kobe Univ, Grad Sch Med, Dept Internal Med, Div Resp Med, Kobe, Hyogo, Japan

[2] Hiroshima City Hiroshima Citizens Hosp, Dept Resp Med, Hiroshima, Japan

[3] Natl Hosp Org Toneyama Hosp, Dept Thorac Oncol, Toyonaka, Osaka, Japan

[4] Izumi Municipal Hosp Canc Ctr, Med Oncol, Izumi, Japan

[5] NHO Nagoya Med Ctr, Dept Resp Med, Nagoya, Aichi, Japan

[6] Kobe City Med Ctr Gen Hosp, Dept Resp Med, Kobe, Hyogo, Japan

[7] Sendai Kousei Hosp, Dept Pulm Med, Sendai, Miyagi, Japan

[8] Kanagawa Cardiovasc & Resp Med, Dept Resp Med, Yokohama, Kanagawa, Japan

[9] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama, Japan

[10] Osaka Metropolitan Univ, Grad Sch Med, Clin Oncol Dept, Osaka, Japan

[11] Hyogo Canc Ctr, Resp Med Dept, Akashi, Hyogo, Japan

[12] Japanese Red Cross Okayama Hosp, Dept Resp Med, Okayama, Japan

[13] Takarazuka City Hosp, Med Oncol Dept, Takarazuka, Hyogo, Japan

[14] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan

[15] Kyoto Univ, Fac Med, Kyoto, Japan

[16] Kindai Univ, Sch Med, Med Oncol Dept, Main Campus, Osaka, Japan

[17] Kyushu Univ, Dept Resp Med, Fukuoka, Japan

[18] Wakayama Med Univ, Internal Med 3, Wakayama, Japan

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.10.672

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

639P

引用

页码：S1642 / S1642

页数：1

共 50 条

[21] Irinotecan, carboplatin, and bevacizumab in untreated extensive-stage small-cell lung cancer
Spigel, David R.
Hainsworth, John D.
Burris, Howard A.
Yardley, Denise A.
Farley, Cindy
Meng, Christina
Greco, Anthony F.
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S391 - S391
[22] Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: A phase II trial of the minnie pearl cancer research network
Spigel, David R.
Hainsworth, John D.
Simons, Lisa
Meng, Christina
Burris, Howard A., III
Yardley, Denise A.
Grapski, Richard
Schreeder, Marshall
Mallidi, Padmaja V.
Greco, F. Anthony
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (09) : 854 - 861
[23] h Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial
Shi, Yuankai
Hu, Yi
Hu, Xingsheng
Li, Xue
Lin, Lin
Han, Xiaohong
THORACIC CANCER, 2015, 6 (06) : 785 - 791
[24] Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer
Lara, Primo N., Jr.
Gandara, David R.
Natale, Ronald B.
CLINICAL LUNG CANCER, 2006, 7 (05) : 353 - 356
[25] Three-week versus four-week schedule of cisplatin plus irinotecan for extensive-stage small cell lung cancer: Phase II study
Lee, J. E.
Lee, Y. J.
Jeong, M. K.
Park, H. S.
Jung, S. S.
Kim, J. O.
Lim, S. -P
Cho, M. J.
Jeong, E.
Yang, S.
Kim, H.
Kim, S. Y.
LUNG CANCER, 2006, 52 : S37 - S37
[26] Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer
Zhou, Zheng-tao
Zhou, Fu-xiang
Wei, Qing
Zou, Li-yong
Qin, Bin-fang
Peng, Xu-shen
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (04) : 1027 - 1032
[27] Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer
Zheng-tao Zhou
Fu-xiang Zhou
Qing Wei
Li-yong Zou
Bin-fang Qin
Xu-shen Peng
Cancer Chemotherapy and Pharmacology, 2011, 68 : 1027 - 1032
[28] Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer
Ohe, Y
Negoro, S
Matsui, K
Nakagawa, K
Sugiura, T
Takada, Y
Nishiwaki, Y
Yokota, S
Kawahara, M
Saijo, N
Fukuoka, M
Ariyoshi, Y
ANNALS OF ONCOLOGY, 2005, 16 (03) : 430 - 436
[29] Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer
Spigel, David R.
Greco, F. Anthony
Zubkus, John D.
Murphy, Patrick B.
Saez, Ruben A.
Farley, Cindy
Yardley, Denise A.
Burris, Howard A., III
Hainsworth, John D.
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (12) : 1555 - 1560
[30] Retrospective study of irinotecan/cisplatin followed by etoposide/cisplatin or the reverse sequence in extensive-stage small cell lung cancer
Xiao, Xiaoguang
Wang, Shujing
Xia, Shu
Zou, Man
Li, Yang
Wei, Yao
Mei, Qi
Chen, Yuan
ONCOTARGETS AND THERAPY, 2015, 8 : 2209 - 2214

← 1 2 3 4 5 →